Pharma news - Regeneron secures European approval for innovative lymphoma drug Ordspono

Pharma News: Regeneron Pharmaceuticals has achieved a significant milestone with the European Commission's approval of its bispecific antibody drug, Ordspono (odronextamab), for the treatment of two types of lymphoma. This approval marks a crucial step for the company, especially after facing rejection from the U.S. Food and Drug Administration (FDA). The European Commission's decision now allows Ordspono to be used across 27 European Union countries, providing a new therapeutic option for patients who have undergone two or more lines of systemic therapy, including cell-based therapies.
https://investor.regeneron.com/news-releases/news-release-details/ordsponotm-odronextamab-approved-european-union-treatment
 
This Pharma News report explores the key findings and implications of this approval.


Pharma news - Regeneron secures European approval for innovative lymphoma drug Ordspono

A New Hope for Lymphoma Patients in Europe
Ordspono is designed to treat relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). These are both aggressive forms of non-Hodgkin lymphoma that often resist standard treatments. The approval in Europe is based on promising results from Phase 2 clinical trials, where Ordspono demonstrated impressive efficacy. In patients with follicular lymphoma, the drug achieved partial or complete responses in 80% of cases. For those with diffuse large B-cell lymphoma, approximately 50% responded to the treatment. These results offer hope to patients who have exhausted other treatment options.
 
Despite its success in Europe, Regeneron faced a setback earlier this year when the U.S. FDA rejected its application for accelerated approval of Ordspono. The rejection was not due to concerns over the drug's effectiveness or safety but rather related to the U.S. FDA's demand for more mature data from confirmatory trials. These trials are essential to verify the initial Phase 2 results and to ensure that the drug provides a sustained benefit. As of now, Regeneron has not announced when it will resubmit its application to the U.S. FDA.
 
Understanding Bispecific Antibodies and Their Role in Cancer Treatment
Ordspono is part of a relatively new class of drugs known as bispecific antibodies. These drugs are engineered to bind simultaneously to two different types of molecules - one on cancer cells and another on immune cells. This dual binding action stimulates the immune system to attack and destroy the cancer cells. Bispecific antibodies have garnered attention as a more convenient alternative to CAR-T cell therapies, which are highly effective but involve complex manufacturing processes and are tailored to each individual patient.
 
The approval of Ordspono in Europe makes it Regeneron’s first bispecific antibody to reach the market. This milestone is significant not only for the company but also for the broader oncology field, where there is growing interest in off-the-shelf treatments that are easier to administer than CAR-T therapies. Unlike CAR-T treatments, which are given in a single dose, bispecific antibodies like Ordspono require ongoing administration. Patients need to return to healthcare facilities for regular infusions, which, although more convenient than CAR-T, still present challenges in terms of patient compliance and healthcare resources.
 
The European Commission's Decision and Its Implications
The European Commission's approval of Ordspono is a testament to the drug's potential to transform the treatment landscape for lymphoma. The decision was supported by robust data from clinical trials, particularly the ELM-2 study. In this trial, follicular lymphoma patients showed an overall response rate (ORR) of 80%, with 73% achieving complete remission. The median duration of response for these complete responders was 25 months, indicating that the drug’s effects are not only powerful but also durable.
 
For patients with diffuse large B-cell lymphoma who had not previously undergone CAR-T therapy, the ORR was 52%, with 31% achieving complete remission. These results are particularly encouraging for patients who have limited treatment options left. The fact that Ordspono can offer such outcomes, even in heavily pretreated patients, underscores its potential as a game-changing therapy in the fight against lymphoma.
 
Challenges and Opportunities Ahead
While the European approval is a major win for Regeneron, the company still faces challenges in the global market. The FDA's initial rejection highlights the stringent requirements for accelerated approval in the U.S., especially in light of recent scrutiny over drugs that failed to demonstrate long-term benefits. The FDA has been tightening its accelerated approval program, which allows drugs to reach the market based on early data but requires confirmatory trials to verify the results. This tightening is in response to concerns that some drugs approved under this pathway have not lived up to their initial promise.
 
Regeneron must now focus on completing its confirmatory trials to meet the FDA’s requirements. The company has acknowledged that it needs to agree on trial timelines with the U.S. FDA before it can resubmit Ordspono for approval. The outcome of these discussions will be crucial for the drug's future in the U.S. market, where the competition is fierce.
 
Competition in the Bispecific Antibody Space
Regeneron is not alone in the race to develop bispecific antibodies for lymphoma. In the past 15 months, several other companies have received FDA approval for similar drugs. AbbVie and Genmab's Epkinly and Roche's Columvi are among the bispecific antibodies now available for treating follicular lymphoma and diffuse large B-cell lymphoma. These drugs, like Ordspono, are approved for use in patients who have failed multiple lines of therapy, making them direct competitors in the same treatment space.
 
To stay ahead, Regeneron is likely to explore combination therapies that could move Ordspono into earlier lines of treatment. Combining bispecific antibodies with other cancer therapies is a strategy being pursued by many companies in the oncology field, as it holds the potential to enhance efficacy and expand the patient population that can benefit from these drugs.
 
Conclusion
Regeneron's Ordspono represents a significant advancement in the treatment of lymphoma, offering new hope to patients in Europe who have exhausted other options. The drug's approval by the European Commission underscores its potential as a valuable addition to the oncology arsenal. However, the road ahead is not without challenges. Regeneron must navigate the complex regulatory landscape in the U.S. and demonstrate that Ordspono can provide lasting benefits to patients. If successful, Ordspono could become a cornerstone of Regeneron's oncology portfolio and a key player in the global bispecific antibody market.
 
For the latest Pharma News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/sanofi-s-children-allergy-medications-recalled-in-india-due-to-possible-microbiological-contamination
 
https://www.thailandmedical.news/news/asceneuron-secures-100-million-dollars-for-new-alzheimer-drug